Published in Mov Disord on April 30, 2007
Mutations in GNAL cause primary torsion dystonia. Nat Genet (2012) 3.66
SGCE isoform characterization and expression in human brain: implications for myoclonus-dystonia pathogenesis? Eur J Hum Genet (2010) 1.05
The treatment of movement disorders by deep brain stimulation. Neurotherapeutics (2008) 0.96
Abnormal nuclear envelopes in the striatum and motor deficits in DYT11 myoclonus-dystonia mouse models. Hum Mol Genet (2011) 0.85
Recent advances in the genetics of dystonia. Curr Neurol Neurosci Rep (2014) 0.84
Myoclonus-dystonia syndrome due to tyrosine hydroxylase deficiency. Neurology (2012) 0.80
Treating complex movement disorders in children with cerebral palsy. Ulster Med J (2009) 0.80
Myoclonus dystonia and muscular dystrophy: ɛ-sarcoglycan is part of the dystrophin-associated protein complex in brain. Mov Disord (2016) 0.79
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol (2008) 6.76
Blinding in randomised trials: hiding who got what. Lancet (2002) 5.47
Phenomenology and classification of dystonia: a consensus update. Mov Disord (2013) 4.98
Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol (2010) 4.77
From psychogenic movement disorder to functional movement disorder: it's time to change the name. Mov Disord (2013) 4.77
Allocation concealment in randomised trials: defending against deciphering. Lancet (2002) 4.71
Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord (2003) 4.56
De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. Nat Genet (2012) 4.51
The comparative safety of legal induced abortion and childbirth in the United States. Obstet Gynecol (2012) 4.50
Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA (2002) 4.38
Generation of allocation sequences in randomised trials: chance, not choice. Lancet (2002) 4.35
Sample size calculations in randomised trials: mandatory and mystical. Lancet (2005) 4.30
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
Mutations in GNAL cause primary torsion dystonia. Nat Genet (2012) 3.66
Rare-disease genetics in the era of next-generation sequencing: discovery to translation. Nat Rev Genet (2013) 3.42
Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol (2003) 3.22
Dependence of subthalamic nucleus oscillations on movement and dopamine in Parkinson's disease. Brain (2002) 3.15
Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology (2006) 3.10
Criteria for the diagnosis of corticobasal degeneration. Neurology (2013) 3.07
Hemiballism: revisiting a classic disorder. Lancet Neurol (2003) 3.00
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol (2003) 2.93
Electronic fetal monitoring as a public health screening program: the arithmetic of failure. Obstet Gynecol (2010) 2.89
Colonic mucosal a-synuclein lacks specificity as a biomarker for Parkinson disease. Neurology (2015) 2.88
Second-trimester abortion for fetal anomalies or fetal death: labor induction compared with dilation and evacuation. Obstet Gynecol (2011) 2.83
Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol (2008) 2.79
Stereotypies: a critical appraisal and suggestion of a clinically useful definition. Mov Disord (2011) 2.76
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol (2010) 2.67
A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain (2008) 2.65
Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results. Mov Disord (2014) 2.64
Sample size slippages in randomised trials: exclusions and the lost and wayward. Lancet (2002) 2.62
Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord (2006) 2.53
Epidemiologic research using administrative databases: garbage in, garbage out. Obstet Gynecol (2010) 2.50
Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol (2009) 2.46
Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol (2007) 2.40
Case-control studies: research in reverse. Lancet (2002) 2.38
Multiplicity in randomised trials II: subgroup and interim analyses. Lancet (2005) 2.34
Alimentary, my dear Watson? The challenges of enteric α-synuclein as a Parkinson's disease biomarker. Mov Disord (2013) 2.32
Multiplicity in randomised trials I: endpoints and treatments. Lancet (2005) 2.32
Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutation. Ann Neurol (2003) 2.23
Stimulation of the subthalamic nucleus in Parkinson's disease does not produce striatal dopamine release. Neurosurgery (2003) 2.21
Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Mov Disord (2010) 2.20
Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord (2004) 2.19
Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology (2012) 2.18
Beta oscillatory activity in the subthalamic nucleus and its relation to dopaminergic response in Parkinson's disease. J Neurophysiol (2006) 2.18
Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. Mov Disord (2012) 2.18
Emergency contraception: politics trumps science at the U.S. Food and Drug Administration. Obstet Gynecol (2004) 2.14
Mutations in SLC20A2 are a major cause of familial idiopathic basal ganglia calcification. Neurogenetics (2013) 2.11
Short and long latency afferent inhibition in Parkinson's disease. Brain (2003) 2.02
Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease. J Neurosurg (2003) 2.01
Bilateral globus pallidus stimulation for Huntington's disease. Ann Neurol (2004) 2.00
Analysis of the glucocerebrosidase gene in Parkinson's disease. Mov Disord (2005) 1.99
A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease. Mov Disord (2008) 1.98
An international effort towards developing standards for best practices in analysis, interpretation and reporting of clinical genome sequencing results in the CLARITY Challenge. Genome Biol (2014) 1.95
Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology (2012) 1.91
Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol (2007) 1.86
Levodopa response in long-term bilateral subthalamic stimulation for Parkinson's disease. Mov Disord (2007) 1.82
Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. Lancet Neurol (2013) 1.82
Association between early-onset Parkinson disease and 22q11.2 deletion syndrome: identification of a novel genetic form of Parkinson disease and its clinical implications. JAMA Neurol (2013) 1.81
Psychogenic movement disorders. Curr Opin Neurol (2009) 1.81
Overview of the extranigral aspects of Parkinson disease. Arch Neurol (2009) 1.79
Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol (2010) 1.77
Impulse control disorders in Parkinson disease: a multicenter case--control study. Ann Neurol (2011) 1.73
Premotor Parkinson's disease: concepts and definitions. Mov Disord (2012) 1.70
Education for contraceptive use by women after childbirth. Cochrane Database Syst Rev (2012) 1.68
Caffeine in Parkinson's disease: a pilot open-label, dose-escalation study. Mov Disord (2011) 1.66
Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation. Arch Neurol (2011) 1.65
TMEM237 is mutated in individuals with a Joubert syndrome related disorder and expands the role of the TMEM family at the ciliary transition zone. Am J Hum Genet (2011) 1.65
Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord (2014) 1.63
Multiple system atrophy-parkinsonism with slow progression and prolonged survival: a diagnostic catch. Mov Disord (2012) 1.63
Potential placebo effect in assessing idiopathic normal pressure hydrocephalus. J Neurosurg (2011) 1.63
Analysis of the PINK1 gene in a large cohort of cases with Parkinson disease. Arch Neurol (2004) 1.63
Stimulation of the subthalamic nucleus and impulsivity: release your horses. Ann Neurol (2009) 1.62
Hormonal contraceptives for contraception in overweight or obese women. Cochrane Database Syst Rev (2010) 1.61
Localization of clinically effective stimulating electrodes in the human subthalamic nucleus on magnetic resonance imaging. J Neurosurg (2002) 1.60
Predictors of deterioration in health-related quality of life in Parkinson's disease: results from the DATATOP trial. Mov Disord (2008) 1.59
Whispering dysphonia (DYT4 dystonia) is caused by a mutation in the TUBB4 gene. Ann Neurol (2013) 1.58
Haploinsufficiency of a spliceosomal GTPase encoded by EFTUD2 causes mandibulofacial dysostosis with microcephaly. Am J Hum Genet (2012) 1.57
Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. Lancet Neurol (2012) 1.54
Pathological gambling in Parkinson's disease improves on chronic subthalamic nucleus stimulation. Mov Disord (2006) 1.54
Distribution, type, and origin of Parkin mutations: review and case studies. Mov Disord (2004) 1.54
Clinical features of dopamine agonist withdrawal syndrome in a movement disorders clinic. J Neurol Neurosurg Psychiatry (2012) 1.54
Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias. Brain (2006) 1.53
Opinions and clinical practices related to diagnosing and managing patients with psychogenic movement disorders: An international survey of movement disorder society members. Mov Disord (2009) 1.53
Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease? Neuropsychopharmacology (2009) 1.51
Social desirability bias in family planning studies: a neglected problem. Contraception (2009) 1.50
Progressive ataxia and palatal tremor (PAPT): clinical and MRI assessment with review of palatal tremors. Brain (2004) 1.47
Mutations in EZH2 cause Weaver syndrome. Am J Hum Genet (2011) 1.46
Dystonia as a presenting sign of spinocerebellar ataxia type 1. Mov Disord (2004) 1.46
Long-term hardware-related complications of deep brain stimulation. Neurosurgery (2002) 1.46
Motor cortical stimulation for parkinsonism in multiple system atrophy. Arch Neurol (2003) 1.45
Do dyskinesia and pain share common pathophysiological mechanisms in Parkinson's disease? Mov Disord (2008) 1.45
Unequal group sizes in randomised trials: guarding against guessing. Lancet (2002) 1.45
Another face of placebo: the lessebo effect in Parkinson disease: meta-analyses. Neurology (2014) 1.45
Strategies to improve adherence and acceptability of hormonal methods of contraception. Cochrane Database Syst Rev (2011) 1.44
The fragile X premutation presenting as essential tremor. Arch Neurol (2003) 1.43
Sex hormone-binding globulin: not a surrogate marker for venous thromboembolism in women using oral contraceptives. Contraception (2008) 1.43
Mutations in PIK3R1 cause SHORT syndrome. Am J Hum Genet (2013) 1.43
α-Synuclein oligomers and clinical implications for Parkinson disease. Ann Neurol (2012) 1.42